FT Global Pharmaceutical & Biotechnology Conference 2012

04 December 2012 - 05 December 2012

08:00 to 18:00 Local Event Time (UTC)

Location: London


Now Available On Demand

Opening Remarks from the Chair
Tuesday, 04 December 2012
9:00 - 9:05 (Utc time)
9:00 - 9:05 (Local time)
Value Based Pricing – Balancing Innovation and Affordability
Tuesday, 04 December 2012
9:05 - 9:55 (Utc time)
9:05 - 9:55 (Local time)

Governments in an ever increasing number of countries are considering cost containment measures as a way to control escalating healthcare costs, and ‘value based pricing’ (VBP) is set to become part of the UK system in January 2014. The move is controversial, setting proponents, who see the opportunity for improved access, cost effectiveness and transition to an integrated care against those who fear for the impact the new regime will have on the willingness and ability of life science companies to develop vital new drugs. What will VBP look like, what are the implications for innovation?Will the benefits outweigh the risks?

The Future of R&D
Tuesday, 04 December 2012
10:20 - 10:45 (Utc time)
10:20 - 10:45 (Local time)
Real World Evidence - Capturing the Value of Pharma
Tuesday, 04 December 2012
10:45 - 11:30 (Utc time)
10:45 - 11:30 (Local time)

With the advent of value based pricing comes the need for life sciences companies to compile real world evidence (RWE) - information which derives from the study of real life effects of their medicines in clinical and real world settings in order to ‘prove’ the value of their products. The move to RWE has significant practical and strategic implications for life science companies. It will mean finding, integrating and analysing vast arrays of data about the benefits and outcomes of treatments with their products, and ensuring that this evidence is credible and able to meet the needs of multiple stockholders. RWE has the potential to transform the business and competitive landscape of the industry. What are the challenges of RWE, and how do companies prepare/build RWE capabilities?

Keynote Interview
Tuesday, 04 December 2012
11:30 - 12:00 (Utc time)
11:30 - 12:00 (Local time)
The New Operating Models of Pharma
Tuesday, 04 December 2012
12:00 - 13:00 (Utc time)
12:00 - 13:00 (Local time)

Radical reform in the way healthcare is delivered and paid for have the potential to transform the operating model and create new revenue streams for life science companies. The move to VBP and the new focus on ‘treatment pathways’ affords the opportunity to maximise revenues both from the product, and through the sale of new health management services relating to prevention, treatment and aftercare. But opportunity itself is no guarantee of success. In this space, life science companies will encounter numerous players with expertise in data,in service delivery, and in technology who will compete for market share. Who will be the winners and what role can life science companies play in these new markets?

Schedules: Schedule Export Print

Scroll down to see the full agenda